Pilot Study on Using the oXiris Hemofiltration Membrane to Improve Blood Pressure and Remove Vasoactive Substances in Critically Ill Patients with Vasoplegic Shock

What this Trial Is About

Researchers are investigating the use of the oXiris hemofiltration membrane in critically ill patients with vasoplegic shock, a condition where blood pressure is dangerously low due to an inappropriate response to infection. This observational pilot study aims to understand how blood purification with the oXiris membrane affects hemodynamics and the clearance of vasoactive metabolites, including angiotensin peptides, which may play a role in vascular tone regulation. Prior clinical data suggest that this treatment may reduce the need for vasopressors in both pediatric and adult patients. The study involves using the oXiris membrane hemofiltration with the Prismaflex system and specific dialysis solutions. Anticoagulation is managed with heparin, citrate, or none depending on bleeding risk. The treatment volume is capped at 35 mlkgh. Blood samples will be collected before treatment, at 24 hours, and at 72 hours to measure angiotensin peptides and related enzymes using advanced laboratory techniques. The samples are analyzed both immediately and after incubation to assess metabolite concentrations. Participants will be monitored for 90 days to track mortality and clinical progress. Data collected from medical records and lab tests will be entered into a database for analysis. The main outcome is a 50% reduction in the vaso-inotropic score within 24 hours after starting treatment. Additional outcomes include changes in vaso-inotropic scores over 72 hours, levels of angiotensins and regulatory enzymes, markers of endothelial function and immune response, and hemodynamic responses. This comprehensive monitoring aims to clarify the biological effects of oXiris treatment in vasoplegic shock.

Clearance of Vasoactive Metabolites With Blood Purification